Related Experiment Videos
Candida parapsilosis sepsis in patients with burns: report of six cases
The Journal of Burn Care & Rehabilitation
|May 1, 1994
Abstract:
Six patients with burns who had Candida Parapsilosis septicemia were encountered during a 3-year period at a regional burn unit. Four patients treated with Amphotericin B survived; two untreated patients did not. Candida Parapsilosis seems to be increasing in frequency at our unit. The organism is somewhat more resistant to antifungal agents than are other Candida species.
Insights
Candida Parapsilosis septicemia in burn patients is increasing and poses a treatment challenge. Amphotericin B treatment improved survival rates in affected individuals.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Burn Care
Background:
- Candida Parapsilosis septicemia presents a growing concern in burn units.
- This fungal pathogen exhibits increased resistance to antifungal agents compared to other Candida species.
Purpose of the Study:
- To report on the incidence and outcomes of Candida Parapsilosis septicemia in burn patients.
- To evaluate the efficacy of Amphotericin B in treating this specific fungal infection.
Main Methods:
- Retrospective analysis of six burn patients with Candida Parapsilosis septicemia over a three-year period.
- Comparison of survival rates between treated and untreated patients.
Main Results:
- Four of the six patients with Candida Parapsilosis septicemia survived after treatment with Amphotericin B.
- Two untreated patients with the infection did not survive.
- Candida Parapsilosis demonstrated higher resistance to antifungals than other Candida species.
Conclusions:
- Candida Parapsilosis septicemia is an emerging threat in burn units, requiring vigilant monitoring.
- Amphotericin B appears to be an effective treatment for Candida Parapsilosis septicemia in burn patients.
- The increased antifungal resistance of Candida Parapsilosis necessitates further research into treatment strategies.